{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:12:10Z","timestamp":1787026330685,"version":"build-2736575974"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to evaluate the clinical efficacy, safety, and impact on outcomes of levosimendan compared with dobutamine in patients with septic cardiomyopathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A randomized clinical trial was conducted in patients with septic cardiomyopathy between December 2022 and March 2024. Eligible patients received either levosimendan or dobutamine in addition to standard sepsis treatments. Baseline characteristics, laboratory parameters, pulse index continuous cardiac output, clinical outcomes, and adverse reactions were recorded and compared between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 50 patients were analyzed, with 25 patients in each group. The mean age was 76.4 (\u00b112.3) years, and 28 patients (56%) were male. Baseline characteristics were comparable between groups. Following treatment, improvements were observed in both groups in left ventricular ejection fracture and levels of cardiac troponin I, B-type natriuretic peptide, cardiac index (CI), lactate, and norepinephrine infusion rate(all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05), with significantly greater improvements in the levosimendan group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). Additionally, the CI was higher in the levosimendan group compared to the dobutamine group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). No statistically significant differences were observed between groups in other pulse index continuous cardiac output variables, laboratory tests, clinical outcomes, or adverse reactions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with septic cardiomyopathy, levosimendan treatment resulted in greater improvements in cardiac function, hemodynamic stability, and tissue perfusion compared with dobutamine, without an increase in adverse reactions. Further studies are needed to evaluate the long-term effects of levosimendan on clinical outcomes in this patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration number<\/jats:title>\n                    <jats:p>ChiCTR2500101261.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2025.1641604","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T05:31:46Z","timestamp":1758259906000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Levosimendan versus dobutamine in septic cardiomyopathy: a randomized clinical trial on cardiac function and safety"],"prefix":"10.3389","volume":"12","author":[{"given":"Feng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuxian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/CCM.0000000000002851","article-title":"Septic cardiomyopathy","volume":"46","author":"Beesley","year":"2018","journal-title":"Crit Care Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100767","DOI":"10.1016\/j.cpcardiol.2020.100767","article-title":"Septic cardiomyopathy: from basics to management choices","volume":"46","author":"Ravikumar","year":"2021","journal-title":"Curr Probl Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3390\/medicina60050751","article-title":"The effects of dobutamine in septic shock: an updated narrative review of clinical and experimental studies","volume":"60","author":"Dubin","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00134-018-5242-5","article-title":"A global perspective on vasoactive agents in shock","volume":"44","author":"Annane","year":"2018","journal-title":"Intensive Care Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.pharmthera.2007.01.008","article-title":"Levosimendan: beyond its simple inotropic effect in heart failure","volume":"114","author":"Antoniades","year":"2007","journal-title":"Pharmacol Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1056\/NEJMoa1609409","article-title":"Levosimendan for the prevention of acute organ dysfunction in sepsis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1007\/s00134-019-05731-w","article-title":"Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial","volume":"45","author":"Antcliffe","year":"2019","journal-title":"Intensive Care Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"20333","DOI":"10.1038\/s41598-021-99716-9","article-title":"Levosimendan versus dobutamine for sepsis-induced cardiac dysfunction: a systematic review and meta-analysis","volume":"11","author":"Liu","year":"2021","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11886-020-01277-2","article-title":"Sepsis-induced cardiomyopathy: a comprehensive review","volume":"22","author":"L'Heureux","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41569-020-00492-2","article-title":"Pathophysiology of sepsis-induced cardiomyopathy","volume":"18","author":"Hollenberg","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00134-013-2982-0","article-title":"Effects of dobutamine on systemic, regional and microcirculatory perfusion parameters in septic shock: a randomized, placebo-controlled, double-blind, crossover study","volume":"39","author":"Hernandez","year":"2013","journal-title":"Intensive Care Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"696138","DOI":"10.3389\/fcvm.2021.696138","article-title":"Inotrope use and intensive care unit mortality in patients with cardiogenic shock: an analysis of a large electronic intensive care unit database","volume":"8","author":"Gao","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.jvca.2022.10.032","article-title":"Efficacy of levosimendan in the treatment of patients with severe septic cardiomyopathy","volume":"37","author":"Sun","year":"2023","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3390\/life13061346","article-title":"Levosimendan in the treatment of patients with severe septic cardiomyopathy","volume":"13","author":"Tsolaki","year":"2023","journal-title":"Life (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.21037\/atm.2017.12.26","article-title":"Severe sepsis and cardiac arrhythmias","volume":"6","author":"Shahreyar","year":"2018","journal-title":"Ann Transl Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e019338","DOI":"10.1136\/bmjopen-2017-019338","article-title":"Effect of levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials","volume":"8","author":"Chang","year":"2018","journal-title":"BMJ Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/apha.12248","article-title":"Levosimendan improves contractility in vivo and in vitro in a rodent model of post-myocardial infarction heart failure","volume":"210","author":"Kolseth","year":"2014","journal-title":"Acta Physiol (Oxf)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1177\/0300060519837103","article-title":"Levosimendan as a new force in the treatment of sepsis-induced cardiomyopathy: mechanism and clinical application","volume":"47","author":"Yang","year":"2019","journal-title":"J Int Med Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1097\/01.CCM.0000261889.18102.84","article-title":"Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone","volume":"35","author":"Barraud","year":"2007","journal-title":"Crit Care Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"R166","DOI":"10.1186\/cc10307","article-title":"Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study","volume":"15","author":"Hasslacher","year":"2011","journal-title":"Crit Care"},{"key":"B23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/SHK.0000000000000851","article-title":"Effects of levosimendan on cellular metabolic alterations in patients with septic shock: a randomized controlled pilot study","volume":"48","author":"Hajjej","year":"2017","journal-title":"Shock"},{"key":"B24","doi-asserted-by":"publisher","first-page":"R232","DOI":"10.1186\/cc9387","article-title":"Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study","volume":"14","author":"Morelli","year":"2010","journal-title":"Crit Care"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.12659\/MSM.898457","article-title":"Levosimendan versus dobutamine in myocardial injury patients with septic shock: a randomized controlled trial","volume":"22","author":"Meng","year":"2016","journal-title":"Med Sci Monit"},{"key":"B26","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1186\/s13054-014-0652-4","article-title":"Levosimendan attenuates multiple organ injury and improves survival in peritonitis-induced septic shock: studies in a rat model","volume":"18","author":"Tsao","year":"2014","journal-title":"Crit Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jcrc.2015.05.017","article-title":"Levosimendan reduces mortality in patients with severe sepsis and septic shock: a meta-analysis of randomized trials","volume":"30","author":"Zangrillo","year":"2015","journal-title":"J Crit Care"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1641604\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T05:31:47Z","timestamp":1758259907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1641604\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":27,"alternative-id":["10.3389\/fcvm.2025.1641604"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1641604","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"article-number":"1641604"}}